Reports Q3 revenue $2.6M, consensus $10.2M. “We continue to execute on our multiple clinical stage programs and look forward to sharing Phase 2 data from our chronic hepatitis B MARCH Part B and chronic hepatitis delta SOLSTICE trials at AASLD,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir‘s Chief Executive Officer. “Initiating a new Phase 1 HIV T cell vaccine clinical trial and securing non-dilutive funding from the U.S. government to advance our next generation COVID-19 mAb through Phase 1 is reflective of our ongoing momentum. We are well-funded to both execute on our clinical programs and evaluate complementary external opportunities to strengthen our platforms and pipeline.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIR:
- Vir Biotechnology appoints Jennifer Towne, Ph.D., as Chief Scientific Officer
- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
- Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
- Vir awarded BARDA funding for development of antibody platform technology
